So Consensys IPO + MASK token incomingzoomer (@zoomerfied):[ ZOOMER ]CONSENSYS, THE CREATOR OF METAMASK, TO IPO: AXIOS ...

IPO排队4个月后，江西红板科技股份有限公司（以下简称"红板科技"）即将迈入冲击A股的下一关键节 点。上交所官网显示，公司主板IPO将于10月31日上会。闯关A股背后，红板科技实控人手握超九成股 权，公司2022年、2023年合计分红1.38亿元。此外，报告期各期，公司研发费用率均低于同行业可比公 司均值。针对相关问题，红板科技方面于10月29日接受了北京商报记者的采访。 10月31日IPO上会 根据安排，上交所上市审核委员会定于10月31日召开2025年第48次上市审核委员会审议会议，审核红板 科技首发事项。 天使投资人、资深人工智能专家郭涛告诉北京商报记者，实控人持股比例较高，很可能削弱中小股东监 督效能，损害公司治理科学性。 从业绩表现来看，红板科技近年来净利存在一定波动。财务数据显示，2022—2024年以及2025年上半 年，公司实现营业收入分别约为22.05亿元、23.4亿元、27.02亿元、17.1亿元；对应实现归属净利润分别 约为1.41亿元、1.05亿元、2.14亿元、2.4亿元。 回顾红板科技的发展历程，公司成立于2005年，自成立之初公司技术团队便开始致力于高端精密电路板 产品的研发。公 ...

BilliontoOne (BLLN) is now open for pre-IPO orders on https://t.co/vCNztATkNg!Be among one of the first to submit orders before BLLN’s expected IPO on Nov 6, 2025.Set your limit price and get notified when trading begins. 🔔Secure your spot early 👇https://t.co/Q6C38J1EJ3 https://t.co/AVJ53S08JB ...

审核 | 颂文 "计量"，古时称"度量衡"，是保证测量单位统一和量值准确可靠的活动。随着现代科技的进步，计量校准已从原来的度量衡和时间计量发展到现代的几何 量、热学等领域。 正冲刺深交所创业板的深圳天溯计量检测股份有限公司（以下简称"天溯计量"）便是一家第三方计量检测服务机构。IPO历时两年，公司终于在10月23日 提交注册，进入关键节点。 不过，天溯计量仍面临诸多问题。在行业竞争日益激烈的情况下，天溯计量业绩逆势增长，但增长可持续性遭监管拷问。 与此同时，公司两成盈利依赖税收优惠和政府补贴，盈利能力受到外界质疑。 出品 | 创业最前线 此外，天溯计量的实控人认定遭质疑，公司频频遭到行政处罚……重重挑战之下，天溯计量能否如愿上市？ 天溯计量的创始人为龚天保。早年间，龚天保曾在计量校准行业一线工作，先后担任业务员、区域主管，积累了经验。 2006年，龚天保创立了东莞市溯源计量检测技术有限公司（以下简称"东莞溯源"），开始从事计量校准的市场拓展业务。 2009年6月，龚天保与妻子吴百香共同创办天溯计量的前身天溯有限。2015年，天溯有限进行股改，将东莞溯源的资产注入其中，深耕检验检测行业。 完成股改当年，天溯计量 ...

Group 1 - The article discusses the services provided by IPO Edge, which includes actionable information on growth stocks, first-look IPO filings, previews on upcoming IPOs, an IPO calendar, a database of U.S. IPOs, and a comprehensive guide to IPO investing [1]

Performance Overview - Baron Real Estate Income Fund increased by 5.43% in Q3 2025, outperforming the MSCI US REIT Index which rose by 4.49% [2] - Since inception on December 29, 2017, the Fund's cumulative return is 97.17%, significantly higher than the REIT Index's 41.54% [2][3] Comparative Rankings - As of September 30, 2025, the Fund ranks in the 2nd, 5th, 17th, and 2nd percentiles for the 1-, 3-, 5-year, and since inception periods, respectively, according to Morningstar [4] - The Fund's Institutional Share Class is ranked as the 3rd, 10th, 28th, and 2nd best performing share class in its category for the same periods [4] Market Outlook - The Fund remains optimistic about public real estate prospects, expecting improving business fundamentals and values to contribute to attractive returns [9] - Positive comments from executives of leading real estate companies indicate a potential improvement in real estate fundamentals [12][13][14][15][16] Investment Strategy - The Fund's portfolio consists of 75% REITs, 22% non-REIT real estate companies, and 3.1% cash and cash equivalents as of September 30, 2025 [21] - The Fund's investment approach includes a focus on both REITs and non-REIT real estate companies, allowing for flexibility in capitalizing on market opportunities [20] Sector Analysis - Industrial REITs represent the largest exposure in the Fund, with a positive outlook driven by demand/supply dynamics and e-commerce growth [23] - Health Care REITs and senior housing are expected to benefit from favorable demographic trends and improving fundamentals [27] - The Fund maintains a cautious but optimistic view on office REITs, identifying specific markets with potential for growth [27] Recent Activity - The Fund initiated positions in Jones Lang LaSalle Incorporated and increased holdings in Prologis, Inc. and The Macerich Company during Q3 2025 [44][46][47] - The Fund trimmed its exposure to certain holdings like American Tower Corporation and Equinix, Inc. due to market conditions and growth outlooks [41][49] Future Prospects - The Fund anticipates a pivotal moment for real estate, with expectations of solid growth in business fundamentals and potential for improved valuations [54] - The overall sentiment in the real estate market is cautiously optimistic, with expectations of continued demand exceeding supply [51]

Core Insights - The article discusses the upcoming IPO of Yuwang Biological, a leading fish oil supplier in China, which holds an 8.1% share of the global market and aims to become the first fish oil stock from Shandong [5][29]. Company Overview - Yuwang Biological has evolved from a soybean protein manufacturer to a global leader in food-grade refined fish oil over 30 years, capitalizing on the health consumption upgrade trend [5][6]. - The company was founded by Liu Xiqian, who transitioned from soybean protein to fish oil in the 1990s, establishing the "Forget Me Not" brand and becoming the first domestic producer of DHA/EPA standard products [7][9][10]. - The company has expanded its global presence, exporting to over 60 countries and becoming a key supplier for dietary supplement brands [11][12]. Financial Performance - Yuwang Biological's net profit has more than doubled from 2022 to 2024, reflecting its growth in global market share [14]. - The company plans to use funds from its IPO to strengthen its supply chain, sales channels, and R&D efforts, addressing financial pressures with a debt ratio exceeding 90% by 2024 [29][32]. Market Challenges - The company faces significant risks due to its reliance on external suppliers for raw materials, with 90% of its costs tied to purchasing crude fish oil, primarily imported from Peru [18][19]. - Yuwang's sales strategy heavily depends on third-party traders, which compromises its pricing power and customer relationships [21][22]. - The fish oil market has experienced negative growth from 2020 to 2023, and while there is a slight recovery expected, the growth rate remains low [28]. Competitive Landscape - Competitors like Xinmeijia and international brands such as Swisse have invested significantly in R&D and maintain higher profit margins through direct sales channels [25][26]. - The global fish oil market is shifting from volume expansion to value competition, with a projected growth rate of only 7.9% over the next five years [28]. Future Strategies - Yuwang aims to establish an overseas procurement base in Peru and sign long-term contracts for crude fish oil to mitigate raw material price volatility [29]. - The company plans to develop a direct sales team in Europe and North America to reduce reliance on traders and enhance revenue from direct sales [30]. - R&D investments will focus on pharmaceutical-grade fish oil and specialized products for infants and pets to diversify its product offerings [31].

IPO排队四个月后，江西红板科技股份有限公司(以下简称"红板科技")即将迈入冲击A股的下一关键节点。上交所官网显示，公司主板IPO将 于10月31日上会。闯关A股背后，红板科技实控人手握超九成股权，公司2022年、2023年合计分红1.38亿元。此外，报告期各期，公司研发 费用率均低于同行业可比公司均值。针对相关问题，红板科技方面于10月29日接受了北京商报记者的采访。 资料显示，红板科技专注于印制电路板(PCB)的研发、生产和销售，公司产品目前主要集中在消费电子、汽车电子、高端显示、工业控制、 计算机及周边设备、通讯电子、集成电路等应用领域。公司主板IPO于今年6月28日获得受理，当年7月18日进入问询阶段。 回顾红板科技的发展历程，公司成立于2005年，自成立之初公司技术团队便开始致力于高端精密电路板产品的研发。公司设立时系森泰集团 (2014年更名为协鑫新能源)间接持股的全资子公司，协鑫新能源于2017年8月对外转让其间接持有的公司100%股权。 本次冲击上市，红板科技拟募集资金约20.57亿元，扣除发行费用后将用于年产120万平方米高精密电路板项目。 不过，红板科技IPO迎考背后，报告期各期，公司研发 ...

大公司： 国际奥委会携手阿里巴巴首次推出五环系列首饰 2026年米兰·科尔蒂纳冬奥会开幕倒计时100天之际，奥林匹克天猫官方旗舰店独家首发米兰冬奥会系列 商品。同时，国际奥委会首次推出奥林匹克五环系列首饰，通过天猫平台在中国独家发售。系列商品已 于28日20时起在天猫开售。 消息称英伟达将与三星等韩国公司签署AI芯片供应协议 据知情人士称，美国科技巨头英伟达将向三星电子、SK集团等韩国企业提供人工智能（AI）芯片。本 周，英伟达CEO黄仁勋将出席在韩国庆州举行的亚太经合组织CEO峰会，这是一个与年度APEC领导人 峰会同时举行的以商业为中心的聚会。据消息人士透露，英伟达将与三星电子、SK集团、现代汽车集 团、Naver等4家公司签订供货协议，并将于周五公布。（新浪财经） 宝马加入"开源创新发展推进中心"，成为首个外资车企成员 36氪获悉，10月28日，宝马中国正式加入"开源创新发展推进中心"，成为该中心首个外资车企成员。据 了解，"开源创新发展推进中心"由中国信通院承办，是国家级开源协同创新平台，汇聚政、产、学、 研、用多方力量，推动中国汽车软件技术自主创新与生态共建。 腾讯"碳寻计划"二期全球50强名单发布 ...

Doncasters, an almost 250-year-old UK metal engineering group that supplies Boeing, is exploring an IPO in New York https://t.co/83mD8Jy1Z7 ...